You have full text access to this OnlineOpen article

Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study

  1. C. BONNY1,
  2. H. FONTAINE2,
  3. T. POYNARD3,
  4. C. HÉZODE4,
  5. D. LARREY5,
  6. P. MARCELLIN6,
  7. M. BOURLIÈRE7,
  8. J. P. BRONOWICKI8,
  9. P. MERLE9,
  10. J. P. ZARSKI10,
  11. T. SAPEY11,
  12. C. GUILLEMARD12,
  13. S. UGHETTO13,
  14. C. HENQUELL14,
  15. C. NICOLAS1,
  16. C. ROCHE1,
  17. K. RANDL1,
  18. G. BOMMELAER1,
  19. A. ABERGEL1

Article first published online: 25 JUL 2006

DOI: 10.1111/j.1365-2036.2006.03018.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 24, Issue 4, pages 593–600, August 2006

Additional Information

How to Cite

BONNY, C., FONTAINE, H., POYNARD, T., HÉZODE, C., LARREY, D., MARCELLIN, P., BOURLIÈRE, M., BRONOWICKI, J. P., MERLE, P., ZARSKI, J. P., SAPEY, T., GUILLEMARD, C., UGHETTO, S., HENQUELL, C., NICOLAS, C., ROCHE, C., RANDL, K., BOMMELAER, G. and ABERGEL, A. (2006), Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Alimentary Pharmacology & Therapeutics, 24: 593–600. doi: 10.1111/j.1365-2036.2006.03018.x

Author Information

  1. 1

    Service d'Hépato-Gastroentérologie, Hôtel-Dieu, Clermont-Ferrand

  2. 2

    Service d'Hépatologie, Hôpital Necker

  3. 3

    Service d'Hépato-Gastroentérologie, Hôpital La Pitié Salpetrière, Paris

  4. 4

    Service d'Hépatologie, Hôpital Henri Mondor, Créteil

  5. 5

    Service d'Hépato-Gastroentérologie, CHU de Montpellier

  6. 6

    Service d'Hépato-Gastroentérologie, Hôpital Beaujon, Paris

  7. 7

    Service d'Hépato-Gastroentérologie, Hôpital Saint-Joseph, Marseille

  8. 8

    Service d'Hépato-Gastroentérologie, CHU de Nancy

  9. 9

    Service d'Hépato-Gastroentérologie, Hôpital Edouard Herriot, Lyon

  10. 10

    Service d'Hépato-Gastroentérologie, CHU de Grenoble

  11. 11

    Service d'Hépato-Gastroentérologie, CHR de Châteauroux

  12. 12

    Service d'Hépato-Gastroentérologie, CHU de Caen

  13. 13

    Service d'Epidémiologie, Hôtel-Dieu, Clermont-Ferrand

  14. 14

    Service de Virologie, Faculté de Médecine, Clermont-Ferrand, France

*Dr C. Bonny, Centre d'Hépato-Gastroentérologie, Hôtel-Dieu, Boulevard Léon Malfreyt, 63058 Clermont Ferrand, France. E-mail: cbonny@chu-clermontferrand.fr

Publication History

  1. Issue published online: 25 JUL 2006
  2. Article first published online: 25 JUL 2006
  3. Publication data Submitted 8 December 2005 First decision 12 December 2005 Resubmitted 2 June 2006 Accepted 5 June 2006
Corrected by:

Erratum

Vol. 24, Issue 8, 1268, Article first published online: 20 SEP 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (89K)

Summary

Aim

To assess the rate of sustained virological response in naïve hepatitis C virus-type 5 patients treated by standard interferon or percutaneous endoscopic gastrostomy-interferon (peg-interferon) and ribavirin combination for 48 weeks.

Patients and methods

A total of 87 hepatitis C virus patients were included from 12 centres in France; 28 patients received interferon plus ribavirin and 59 were treated with peg-interferon plus ribavirin.

Results

Baseline characteristics were: mean age 58 ± 11 years, sex ratio 1, 66% had metavir fibrosis score ≥F2, 21% were cirrhotics and 53% had pretherapeutic viral load ≥800 000 IU/mL. Sustained virological response was achieved in 64% and 58% of hepatitis C virus-5 patients treated with interferon and peg-interferon, respectively (NS). In adherent patients, sustained virological response was obtained in 75% of patients. Sustained virological response in hepatitis C virus-5 patients (60%) was significantly higher than sustained virological response in hepatitis C virus-1 patients (37%) (P = 0.0499) and not significantly different from sustained virological response in hepatitis C virus-2–3 patients (63%) (P = 0.8098).

Conclusions

Combination therapy is effective in 60% of hepatitis C virus-5-infected patients. Sustained virological response seems better in hepatitis C virus-5 patients than in hepatitis C virus-1 patients, and is similar to that of hepatitis C virus-2–3 patients. More studies are needed to determine optimal duration of treatment in hepatitis C virus-5 patients.

View Full Article (HTML) Get PDF (89K)